Kymera Therapeutics Inc
KYMR43.385USD
+0.425+0.99%
交易中 （美東）報價延遲15分鐘
2.82B總市值
虧損本益比TTM
關於 Kymera Therapeutics Inc 公司
Kymera Therapeutics, Inc. 是一家生物製藥公司。該公司專注於發現和開發新型小分子療法，通過利用人體自身的天然蛋白質降解系統選擇性地降解致病蛋白質。該公司的靶向蛋白質降解 (TPD) 平臺（稱爲 Pegasus）使其能夠發現具有針對全身致病蛋白質活性的高選擇性小分子蛋白質降解劑。該公司利用其 Pegasus 平臺設計專注於免疫炎症和腫瘤學領域的新型蛋白質降解劑，並繼續將其平臺的功能應用於其他治療領域。其臨牀階段項目是 IRAK4、STAT3 和 MDM2，它們各自針對生物學上已證實的途徑中的高影響目標，爲治療一系列免疫炎症疾病、血液系統惡性腫瘤和/或實體瘤提供了機會。
公司簡介
公司代碼KYMR
公司名稱Kymera Therapeutics Inc
上市日期Aug 21, 2020
CEODr. Nello Mainolfi, Ph.D.
員工數量188
證券類型Ordinary Share
年結日Aug 21
公司地址500 North Beacon Street, 4Th Floor
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02472
電話18572855314
網址https://www.kymeratx.com/
公司代碼KYMR
上市日期Aug 21, 2020
CEODr. Nello Mainolfi, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
67.50K
+23.48%
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Justine Koenigsberg
Ms. Justine Koenigsberg
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bruce N. Jacobs
Mr. Bruce N. Jacobs
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
67.50K
+23.48%
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Justine Koenigsberg
Ms. Justine Koenigsberg
Vice President - Investor Relations
Vice President - Investor Relations
--
--
收入明細
FY2024
暫無數據
地區USD
名稱
營收
佔比
United States
47.07M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Baker Bros. Advisors LP
9.48%
T. Rowe Price Associates, Inc.
9.48%
Avoro Capital Advisors LLC
9.21%
Wellington Management Company, LLP
8.55%
BVF Partners L.P.
7.81%
Other
55.48%
持股股東
持股股東
佔比
Baker Bros. Advisors LP
9.48%
T. Rowe Price Associates, Inc.
9.48%
Avoro Capital Advisors LLC
9.21%
Wellington Management Company, LLP
8.55%
BVF Partners L.P.
7.81%
Other
55.48%
股東類型
持股股東
佔比
Investment Advisor
40.90%
Investment Advisor/Hedge Fund
31.55%
Hedge Fund
22.61%
Venture Capital
8.27%
Individual Investor
1.40%
Corporation
1.10%
Research Firm
0.91%
Private Equity
0.41%
Bank and Trust
0.39%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
393
75.73M
107.94%
-273.58K
2025Q1
408
74.79M
106.76%
-4.90M
2024Q4
392
73.17M
112.73%
-3.17M
2024Q3
379
71.17M
110.57%
-5.78M
2024Q2
360
69.86M
113.52%
-7.55M
2024Q1
364
70.22M
115.13%
-982.70K
2023Q4
350
63.05M
113.62%
-5.46M
2023Q3
341
59.94M
108.11%
-9.64M
2023Q2
349
61.24M
110.72%
-7.83M
2023Q1
353
62.67M
113.41%
-6.15M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Baker Bros. Advisors LP
6.65M
9.48%
+655.50K
+10.93%
Jun 30, 2025
T. Rowe Price Associates, Inc.
6.65M
9.48%
-169.69K
-2.49%
Mar 31, 2025
Avoro Capital Advisors LLC
6.46M
9.21%
+1.31M
+25.44%
Mar 31, 2025
Wellington Management Company, LLP
6.00M
8.55%
+689.55K
+12.99%
Mar 31, 2025
BVF Partners L.P.
5.48M
7.81%
+317.17K
+6.14%
Jun 30, 2025
The Vanguard Group, Inc.
5.22M
7.45%
+344.08K
+7.05%
Mar 31, 2025
Atlas Venture
4.90M
6.98%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.41M
6.28%
-421.36K
-8.72%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.63M
5.17%
-76.67K
-2.07%
Mar 31, 2025
Invus Public Equities Advisors, LLC
3.24M
4.62%
+270.58K
+9.11%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.83%
Harbor Human Capital Factor US Small Cap ETF
0.7%
SPDR S&P Biotech ETF
0.44%
Invesco Nasdaq Biotechnology ETF
0.32%
ProShares Ultra Nasdaq Biotechnology
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
First Trust Multi-Manager Small Cap Opportunities ETF
0.25%
T Rowe Price Small-Mid Cap ETF
0.24%
iShares Biotechnology ETF
0.24%
iShares Russell 2000 Growth ETF
0.14%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.83%
Harbor Human Capital Factor US Small Cap ETF
佔比0.7%
SPDR S&P Biotech ETF
佔比0.44%
Invesco Nasdaq Biotechnology ETF
佔比0.32%
ProShares Ultra Nasdaq Biotechnology
佔比0.32%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.25%
First Trust Multi-Manager Small Cap Opportunities ETF
佔比0.25%
T Rowe Price Small-Mid Cap ETF
佔比0.24%
iShares Biotechnology ETF
佔比0.24%
iShares Russell 2000 Growth ETF
佔比0.14%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
